- Home
- DCTH vs TNXP Comparison
DCTH vs TNXP Comparison
Compare DCTH & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- TNXP
- Stock Information
- Founded
- DCTH 1988
- TNXP 2007
- Country
- DCTH United States
- TNXP United States
- Employees
- DCTH N/A
- TNXP N/A
- Industry
- DCTH Medical/Dental Instruments
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- TNXP Health Care
- Exchange
- DCTH Nasdaq
- TNXP Nasdaq
- Market Cap
- DCTH 394.9M
- TNXP 365.8M
- IPO Year
- DCTH N/A
- TNXP N/A
- Fundamental
- Price
- DCTH $10.96
- TNXP $44.38
- Analyst Decision
- DCTH Strong Buy
- TNXP Buy
- Analyst Count
- DCTH 4
- TNXP 1
- Target Price
- DCTH $24.00
- TNXP $70.00
- AVG Volume (30 Days)
- DCTH 710.7K
- TNXP 1.5M
- Earning Date
- DCTH 08-06-2025
- TNXP 08-15-2025
- Dividend Yield
- DCTH N/A
- TNXP N/A
- EPS Growth
- DCTH N/A
- TNXP N/A
- EPS
- DCTH N/A
- TNXP N/A
- Revenue
- DCTH $53,850,000.00
- TNXP $10,041,000.00
- Revenue This Year
- DCTH $162.10
- TNXP $22.87
- Revenue Next Year
- DCTH $32.97
- TNXP $711.66
- P/E Ratio
- DCTH N/A
- TNXP N/A
- Revenue Growth
- DCTH 1068.87
- TNXP N/A
- 52 Week Low
- DCTH $7.17
- TNXP $6.76
- 52 Week High
- DCTH $18.23
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- DCTH 42.66
- TNXP 56.12
- Support Level
- DCTH $10.44
- TNXP $35.66
- Resistance Level
- DCTH $11.67
- TNXP $46.23
- Average True Range (ATR)
- DCTH 0.46
- TNXP 4.07
- MACD
- DCTH 0.11
- TNXP -0.61
- Stochastic Oscillator
- DCTH 68.03
- TNXP 60.87
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.